TICKERNERD
Menu
RDNTRDNTHealthcare · Diagnostics & Research

RDNT Stock Forecast: RadNet, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$67
+4.74% on the day

The 8 Wall Street analysts covering RadNet, Inc. hold a median 12-month price target of $94 — +40.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 1 Aug 2026 — in the lower half.

Market cap
$5.3B
Ticker Nerd rank
42 / 100
Median analyst target
$94
Analysts covering
8
Total return, dividends reinvested
1W
+8.6%
1M
−2.8%
YTD
−6.4%
1Y
+22.1%
From 52W high
−20.9%
From 52W low
+28.8%
$52
$84
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RDNT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores RadNet, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
42 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
75
Revisions
70
Momentum
63
Accruals
58
Volatility
45
Quality
42
Value
35
Size
24
Issuance
17

Growth (75): Sales and profits are climbing, and climbing faster than before.

Issuance (17): The company has been issuing shares or taking on financing, diluting existing holders.

The rank is the raw material. Whether the rules would actually own RadNet, Inc. — and when they’d sell — is the membership.

Wall Street

RDNT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RDNT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$60$70$80$90$100Oct 25Jan 26Apr 26Jul 26RDNTHigh $100Median $94Low $65

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $65Median $94High $100

The green dot is the last close — the median target sits +40.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 May 2026BarclaysMaintainsOverweight$70 → $65
21 Apr 2026BarclaysMaintainsOverweight—
9 Jan 2026KeybancInitiatesOverweight—
1 Dec 2025B. Riley SecuritiesMaintainsBuy—
13 Nov 2025BarclaysMaintainsOverweight—
12 Nov 2025Truist SecuritiesMaintainsBuy—
3 Sept 2025BarclaysMaintainsOverweight—
3 Sept 2025Truist SecuritiesMaintainsBuy—
13 Aug 2025Raymond JamesReiteratesStrong Buy—
13 June 2025B. Riley SecuritiesInitiatesBuy—
11 Apr 2025Truist SecuritiesMaintainsBuy—
24 Mar 2025BarclaysMaintainsOverweight—
5 Mar 2025Raymond JamesUpgradeStrong Buy—
22 Jan 2025BarclaysMaintainsOverweight—
22 Jan 2025Truist SecuritiesReiteratesBuy—
15 Jan 2025JefferiesMaintainsBuy—
5 Dec 2024JefferiesMaintainsBuy—
4 Dec 2024BarclaysMaintainsOverweight—
29 Nov 2024Truist SecuritiesMaintainsBuy—
23 Sept 2024Truist SecuritiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

RDNT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−18.4%
Analysts raising
2
Analysts cutting
4
Fundamentals

RadNet, Inc. (RDNT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
1425.8×

Cheaper than 1% of US stocks

Price / sales
2.4×

Cheaper than 47% of US stocks

Price / book
4.7×

Cheaper than 22% of US stocks

EV / EBITDA
26.8×

Cheaper than 10% of US stocks

Growth & margins
Revenue growth (YoY)
22.1%

Higher than 74% of US stocks

Earnings growth (YoY)
—
Gross margin
4.4%

Higher than 7% of US stocks

Operating margin
−2.8%

Higher than 32% of US stocks

Net margin
−0.7%

Higher than 29% of US stocks

Returns & dividend
Return on equity
1.8%

Higher than 47% of US stocks

Return on assets
1.6%

Higher than 56% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

RDNT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
RDNTRadNet, Inc.$5.3B
42
SHCSotera Health Co.$5.1B
87
TWSTTwist Bioscience Corp.$5.6B
58
BLLNBillionToOne, Inc.$6.2B
12
VCYTVeracyte, Inc.$3.7B
95
ADPTAdaptive Biotechnologies Corp.$3.6B
77
QGENQiagen NV$8.6B
61
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RDNT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest RDNT news & analysis

DeepHealth Receives FDA Clearance for AI-Powered Breast Ultrasound

GlobeNewsWire · 30 July 2026positive

DeepHealth, a wholly owned subsidiary of RadNet, received FDA 510(k) clearance for its AI-powered breast ultrasound solution, which aims to improve standardization, clinical accuracy, and efficiency in breast ultrasound imaging.

Why it matters — The FDA clearance represents a regulatory milestone for RadNet's subsidiary, potentially expanding the company's AI-driven product offering in medical imaging.

5 Takeover Targets for the AI Revolution

InvestorPlace · 26 July 2026positive

An InvestorPlace article titled "5 Takeover Targets for the AI Revolution" includes RadNet, Inc. as a named takeover target. The excerpt notes that in the 2010s, getting acquired was the ultimate startup status symbol.

Why it matters — RDNT watchers would care because the article positions the company as a potential acquisition target amid the broader AI revolution.

FAQ

Frequently asked questions about RDNT stock

What is the RDNT stock price forecast for 2026-2027?

The 8 Wall Street analysts covering RadNet, Inc. have a median 12-month price target of $94, with estimates ranging from $65 to $100. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RDNT stock a buy right now?

Of the 8 analysts covering RadNet, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks RadNet, Inc. 42 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RDNT?

As at 1 Aug 2026, RadNet, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (75 of 100).

Will RDNT stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +40.0% from the last close, and Ticker Nerd's factor model ranks RadNet, Inc. 42 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RDNT stock forecast for 2030?

No analyst covering RadNet, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RDNT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $65 to $100 over the next 12 months.

How has RDNT stock performed over the past year?

RadNet, Inc. returned +22.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does RadNet, Inc. do?

RadNet Inc. is a healthcare services company that provides outpatient diagnostic imaging across the United States.

What is the latest news on RDNT?

The most recent item we track (GlobeNewsWire, 30 July 2026): "DeepHealth Receives FDA Clearance for AI-Powered Breast Ultrasound". DeepHealth, a wholly owned subsidiary of RadNet, received FDA 510(k) clearance for its AI-powered breast ultrasound solution, which aims to improve standardization, clinical accuracy, and efficiency in breast ultrasound imaging.

Company

About RadNet, Inc.

RadNet Inc. is a healthcare services company that provides outpatient diagnostic imaging across the United States. The company operates a network of freestanding, fixed-site imaging centers that support physicians in diagnosing and monitoring a wide range of diseases and disorders while helping reduce the need for invasive procedures. Its core services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, and fluoroscopy. RadNet Inc. also operates a Digital Health segment that develops clinical applications designed to improve medical image interpretation and support care for areas such as brain, breast, prostate, and pulmonary diagnostics. Through these offerings, RadNet Inc. plays an important role in the delivery of imaging-based care for patients, providers, and health systems.

CEO Dr. Howard G. Berger M.D. · 11,000 employees · United States · https://www.radnet.com